Technical Analysis for PTGX - Protagonist Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| New 52 Week Closing High | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 1.59% | |
| Pocket Pivot | Bullish Swing Setup | 1.59% | |
| Volume Surge | Other | 1.59% | |
| Gapped Up | Strength | 1.59% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 7 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| 2x Volume Pace | about 10 hours ago |
| Up 3% | about 10 hours ago |
| 1.5x Volume Pace | about 11 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/01/2024
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.96 |
| 52 Week Low | 13.72 |
| Average Volume | 699,943 |
| 200-Day Moving Average | 24.25 |
| 50-Day Moving Average | 29.94 |
| 20-Day Moving Average | 32.84 |
| 10-Day Moving Average | 32.60 |
| Average True Range | 1.63 |
| RSI (14) | 65.52 |
| ADX | 23.47 |
| +DI | 32.98 |
| -DI | 16.08 |
| Chandelier Exit (Long, 3 ATRs) | 31.06 |
| Chandelier Exit (Short, 3 ATRs) | 31.90 |
| Upper Bollinger Bands | 35.97 |
| Lower Bollinger Band | 29.71 |
| Percent B (%b) | 0.88 |
| BandWidth | 19.05 |
| MACD Line | 0.89 |
| MACD Signal Line | 0.86 |
| MACD Histogram | 0.0299 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 36.96 | ||||
| Resistance 3 (R3) | 36.97 | 36.39 | 36.66 | ||
| Resistance 2 (R2) | 36.39 | 35.95 | 36.39 | 36.56 | |
| Resistance 1 (R1) | 35.80 | 35.67 | 36.10 | 35.79 | 36.47 |
| Pivot Point | 35.22 | 35.22 | 35.37 | 35.22 | 35.22 |
| Support 1 (S1) | 34.63 | 34.78 | 34.93 | 34.62 | 33.93 |
| Support 2 (S2) | 34.05 | 34.50 | 34.05 | 33.84 | |
| Support 3 (S3) | 33.46 | 34.05 | 33.74 | ||
| Support 4 (S4) | 33.45 |
